ILKAY vs. MRNA

Last updated Jun 24, 2026

ILKAY (Iluka Resources Ltd ADR) and MRNA (Moderna, Inc.) are both stocks. ILKAY operates in Other Industrial Metals & Mining (Basic Materials), while MRNA operates in Biotechnology (Healthcare). Over the past 5 years, ILKAY returned -1.35%/yr vs -22.64%/yr for MRNA. At a 0.05 correlation, their price movements are largely independent.

Performance

ILKAY vs. MRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Iluka Resources Ltd ADR (ILKAY) and Moderna, Inc. (MRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, ILKAY achieves a 41.54% return, which is significantly lower than MRNA's 106.85% return.

ILKAY

• 1D: -7.49%
• 1M: -4.76%
• YTD: 41.54%
• 6M: 37.21%
• 1Y: 124.64%
• 3Y*: -11.65%
• 5Y*: -1.35%
• 10Y*: 10.70%

MRNA

• 1D: 2.79%
• 1M: 30.12%
• YTD: 106.85%
• 6M: 88.91%
• 1Y: 137.63%
• 3Y*: -19.86%
• 5Y*: -22.64%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

ILKAY vs. MRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
ILKAY Iluka Resources Ltd ADR	41.54%	19.25%	-26.93%	-30.67%	-8.72%	83.16%	24.66%	6.24%	0.00%
MRNA Moderna, Inc.	106.85%	-29.08%	-58.19%	-44.63%	-29.28%	143.11%	434.10%	28.09%	-30.59%

Correlation

The correlation between ILKAY and MRNA is 0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.07
Correlation (3Y) Calculated over the trailing 3-year period	0.09
Correlation (5Y) Calculated over the trailing 5-year period	0.08
Correlation (All Time) Calculated using the full available price history since Dec 7, 2018	0.05

Fundamentals

Market Cap ILKAY : $2.25B MRNA : $24.10B
EPS ILKAY : -A$1.11 MRNA : -$8.16
PS Ratio ILKAY : 1.73 MRNA : 10.73
PB Ratio ILKAY : 1.58 MRNA : 3.25
Total Revenue (TTM) ILKAY : A$1.89B MRNA : $2.23B
Gross Profit (TTM) ILKAY : A$789.87M MRNA : -$309.00M
EBITDA (TTM) ILKAY : A$565.16M MRNA : -$3.02B

Return for Risk

ILKAY vs. MRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ILKAY

ILKAY Risk / Return Rank: 81
ILKAY Sharpe Ratio Rank: 84
ILKAY Sortino Ratio Rank: 80
ILKAY Omega Ratio Rank: 81
ILKAY Calmar Ratio Rank: 83
ILKAY Martin Ratio Rank: 78

MRNA

MRNA Risk / Return Rank: 86
MRNA Sharpe Ratio Rank: 89
MRNA Sortino Ratio Rank: 87
MRNA Omega Ratio Rank: 84
MRNA Calmar Ratio Rank: 88
MRNA Martin Ratio Rank: 83

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ILKAY vs. MRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Iluka Resources Ltd ADR (ILKAY) and Moderna, Inc. (MRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	ILKAY	MRNA	Difference
Sharpe ratio: Return per unit of total volatility	1.62	2.08	-0.46
Sortino ratio: Return per unit of downside risk	2.22	2.82	-0.60
Omega ratio: Gain probability vs. loss probability	1.30	1.33	-0.02
Calmar ratio: Return relative to maximum drawdown	2.85	3.90	-1.05
Martin ratio: Return relative to average drawdown	5.43	7.65	-2.22

ILKAY vs. MRNA - Sharpe Ratio Comparison

The current ILKAY Sharpe Ratio is 1.62, which is comparable to the MRNA Sharpe Ratio of 2.08. The chart below compares the historical Sharpe Ratios of ILKAY and MRNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

ILKAY vs. MRNA - Drawdown Comparison

The maximum ILKAY drawdown since its inception was -79.51%, smaller than the maximum MRNA drawdown of -95.38%. Use the drawdown chart below to compare losses from any high point for ILKAY and MRNA.

Drawdown Indicators

	ILKAY	MRNA	Difference
Max Drawdown Largest peak-to-trough decline	-79.51%	-95.38%	+15.87%
Max Drawdown (1Y) Largest decline over 1 year	-43.96%	-35.51%	-8.45%
Max Drawdown (3Y) Largest decline over 3 years	-76.29%	-86.58%	+10.29%
Max Drawdown (5Y) Largest decline over 5 years	-77.94%	-95.38%	+17.44%
Max Drawdown (10Y) Largest decline over 10 years	-77.94%	—	—
Current Drawdown Current decline from peak	-35.85%	-87.41%	+51.56%
Average Drawdown Average peak-to-trough decline	-47.22%	-57.16%	+9.94%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.03%	18.06%	+4.97%

Volatility

ILKAY vs. MRNA - Volatility Comparison

Iluka Resources Ltd ADR (ILKAY) and Moderna, Inc. (MRNA) have volatilities of 21.14% and 21.74%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ILKAY	MRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.14%	21.74%	-0.60%
Volatility (6M) Calculated over the trailing 6-month period	48.27%	51.09%	-2.82%
Volatility (1Y) Calculated over the trailing 1-year period	77.47%	66.45%	+11.02%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	55.24%	66.76%	-11.52%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	51.53%	72.27%	-20.74%

Dividends

ILKAY vs. MRNA - Dividend Comparison

ILKAY's dividend yield for the trailing twelve months is around 0.65%, while MRNA has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ILKAY Iluka Resources Ltd ADR	0.65%	1.03%	1.68%	3.58%	7.39%	1.33%	73.30%	2.45%	4.10%	0.55%	9.11%	2.95%
MRNA Moderna, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both ILKAY and MRNA in my portfolio?

ILKAY and MRNA have a correlation of 0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, ILKAY or MRNA?

MRNA has higher volatility (21.74%) compared to ILKAY (21.14%). In terms of maximum drawdown, ILKAY dropped -79.51% vs MRNA's -95.38%.

Which has better risk-adjusted returns?

MRNA currently has the higher Sharpe Ratio (2.08 vs 1.62), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.